Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Reviews in the Neurosciences

Editor-in-Chief: Huston, Joseph P.

Editorial Board: Topic, Bianca / Adeli, Hojjat / Buzsaki, Gyorgy / Crawley, Jacqueline / Crow, Tim / Gold, Paul / Holsboer, Florian / Korth, Carsten / Li, Jay-Shake / Lubec, Gert / McEwen, Bruce / Pan, Weihong / Pletnikov, Mikhail / Robbins, Trevor / Schnitzler, Alfons / Stevens, Charles / Steward, Oswald / Trojanowski, John

IMPACT FACTOR 2017: 2.590
5-year IMPACT FACTOR: 3.078

CiteScore 2017: 2.81

SCImago Journal Rank (SJR) 2017: 0.980
Source Normalized Impact per Paper (SNIP) 2017: 0.804

See all formats and pricing
More options …
Volume 25, Issue 3


Special issue: potential therapeutic targets involving 5-HT6 and 5-HT7 receptors

Alfredo Meneses / Teresa Ponce-Lopez
  • Facultad de Ciencias de la Salud, Universidad Anáhuac México Norte, Huixquilucan, Estado de México 52786, Mexico e-mail:
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2014-04-04 | DOI: https://doi.org/10.1515/revneuro-2014-0020

Serotonin or 5-hydroxytryptamine (5-HT) has a long history in scientific investigation, ranging from gastrointestinal, feeding, and cardiovascular functions to migraine and emotional and pain problems. 5-HT has multiple receptors, and particularly, the 5-HT6 and 5-HT7 receptors have been shown to be involved in functions and dysfunctions of the central nervous system and have become targets in many laboratories around the world. This special issue of Reviews in the Neurosciences (Rev. Neurosci.) addresses some important physiological, pathophysiological, and potential therapeutic applications of 5-HT6 and 5-HT7 receptors, including sleep regulation, depression, stress, and memory, among others.

Although there are few 5-HT6 receptor-related patents, when all patents are grouped according to the different subtypes of serotonin receptors, 5-HT6 receptors represent 9.47% of the total (see Ruiz and Oranias Olsina, 2010); thus, the 5-HT6 receptor is the fourth target of interest after 5-HT1A, 5-HT2A, and 5-HT1D. When specifically searching for “5-HT6 receptor ligands” and their mechanism of action, 271 different patent families are retrieved (Ruiz and Oranias Olsina, 2010). 5-HT6 receptors have been implicated in the control of memory processes, but in terms of patents, diseases such as depression, obesity, psychosis, pain, and Alzheimer’s disease are also important. Moreover, the growing interest in the 5-HT7 receptor is evidenced by the enlarging range of focuses and approaches, including the synthesis of radioligands, agonists, and antagonists and studies linking these receptors to stress, schizophrenia, age-related memory impairment, sleep, and wakefulness. Other potential areas of interest include addiction, neurotransmission systems (Costa et al., 2012; Pehrson and Sanchez, 2013), intracellular pathways (Gellynck et al., 2013; Seyedabadi et al., 2014), immune responses, and intestinal inflammation (Kim et al., 2013). Thus, the 5-HT6 and 5-HT7 receptors represent a new horizon waiting to be studied with regard to their functions and dysfunctions as well as their therapeutic applications. We hope that the present reviews are successful in showing that 5-HT6 and 5-HT7 receptors modulate different functions, and by this, provide new clues in neuroscience research that encourage new lines of investigation.

We would like to thank all the authors who contributed reviews. All the documents passed through a review process and many anonymous referees helped with their professional comments and corrections. The expertise of external reviewers is widely appreciated. Special thanks to the editor in chief of Rev. Neurosci., Professor Joe Huston, as this special issue would not have been possible without his support, and to the managing editor, Dr. Torsten Krüger and Alice Collins and Holger Kleessen, who have diligently answered all of our questions and corrected our mistakes. Finally, we thank the publisher, Walter de Gruyter GmbH, for supporting this special issue of Rev. Neurosci.


  • Costa, L., Spatuzza, M., D’Antoni, S., Bonaccorso, C.M., Trovato, C., Musumeci, S.A., Leopoldo, M., Lacivita, E., Catania, M.V., and Ciranna, L. (2012). Activation of 5-HT7 serotonin receptors reverses metabotropic glutamate receptor-mediated synaptic plasticity in wild-type and Fmr1 knockout mice, a model of Fragile X syndrome. Biol. Psychiatry 72, 924–933.Web of ScienceGoogle Scholar

  • Gellynck, E., Heyninck, K., Andressen, K.W., Haegeman, G., Levy, F.O., Vanhoenacker, P., and Van Craenenbroeck, K. (2013). The serotonin 5-HT7 receptors: two decades of research. Exp. Brain Res. 230, 555–568.Google Scholar

  • Kim, J.J., Bridle, B.W., Ghia, J.E., Wang, H., Syed, S.N., Manocha, M.M., Rengasamy, P., Shajib, M.S., Wan, Y., Hedlund, P.B., et al. (2013). Targeted inhibition of serotonin type 7 (5-HT7) receptor function modulates immune responses and reduces the severity of intestinal inflammation. J. Immunol. 190, 4795–4804.Google Scholar

  • Pehrson, A.L. and Sanchez, C. (2013). Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr. 1–13. Epub ahead of print.Google Scholar

  • Ruiz, N.V. and Oranias Olsina, G. (2010). Patents. Int. Rev. Neurobiol. 94, 35–66.Google Scholar

  • Seyedabadi, M., Fakhfouri, G., Ramezani, V., Mehr, S.E., and Rahimian, R. (2014). The role of serotonin in memory: interactions with neurotransmitters and downstream signaling. Exp. Brain Res. 232, 723–738.Web of ScienceGoogle Scholar

About the article

Published Online: 2014-04-04

Published in Print: 2014-06-01

Citation Information: Reviews in the Neurosciences, Volume 25, Issue 3, Pages 309–310, ISSN (Online) 2191-0200, ISSN (Print) 0334-1763, DOI: https://doi.org/10.1515/revneuro-2014-0020.

Export Citation

©2014 by Walter de Gruyter Berlin/Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in